These five super-aggressive biotech stocks are all rated Buy at well-known Wall Street firms and are suitable for very aggressive investors that have a high-risk tolerance.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including BlackBerry, BHP, Lam Research, Shopify, Square and Zoom Video Communications.
Affimed shares took a big step back early on Tuesday after the company announced that it has placed its AFM11 on clinical hold, and has notified the global health authorities of its decision.
Affimed shares more than doubled early on Tuesday after it was announced that the firm entered into a strategic collaboration agreement with Genentech.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Affimed, Coty, Cree, Lululemon Athletica, Myriad Genetics, Tesla and Xilinx.
Affimed N.V. (NASDAQ: AFMD) shares dropped sharply early on Friday after the firm released new results from its early stage trial with Keytruda. The firm presented new interim data from the Phase 1b...
Affimed shares rose on Monday following the announcement of a collaboration in immuno-oncology with biotech giant Merck.